Literature DB >> 9255931

Reinfection-induced increase of rubella persistently infected cells in a macrophage-like cell line.

R E Sarmiento1, R Tirado, B Gómez.   

Abstract

The establishment and relevant characteristics of a long-term rubella persistent infected immortalised murine macrophage culture with a high proportion of persistent infected cells over uninfected is described. The high proportion of persistent infected macrophages was obtained through reinfection with the original virus. Prior to reinfection, 35-50% of the cells expressed viral antigen, 0.05-1.5% produced infective virus and extra-cellular virus was continuously produced with infective titers cyclically fluctuating between 10(2) and 10(7) TCID50/ml. After reinfection, the macrophages which expressed viral antigen and produced infective virus had increased to 75-90% and 30-45% respectively and extracellular virus was continuously produced with stable titer between 10(2)-10(3) TCID50/ml. Furthermore, in the reinfected culture no significant variation was observed in the percentage of cells expressing antigen, producing virus and in the titer of extracellular virus for longer than a year of passages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255931     DOI: 10.1016/s0168-1702(97)00048-8

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  2 in total

1.  Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages.

Authors:  M L Linn; L Mateo; J Gardner; A Suhrbier
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies.

Authors:  Ludmila Perelygina; Stanley Plotkin; Pierre Russo; Timo Hautala; Francisco Bonilla; Hans D Ochs; Avni Joshi; John Routes; Kiran Patel; Claudia Wehr; Joseph Icenogle; Kathleen E Sullivan
Journal:  J Allergy Clin Immunol       Date:  2016-09-06       Impact factor: 10.793

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.